Á lódáil...
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Cancer immunotherapy by targeting of immune checkpoint molecules has been a research ‘hot-spot' in recent years. Nivolumab, a human monoclonal antibody targeting PD-1, has been widely used clinically since 2014. However, the binding mechanism of nivolumab to PD-1 has not yet been shown, despite...
Na minha lista:
| Foilsithe in: | Nat Commun |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Nature Publishing Group
2017
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5303876/ https://ncbi.nlm.nih.gov/pubmed/28165004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms14369 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|